Bispecific antibodies are an large engineered family of molecules designed to recognize two different epitopes or antigens simultaneously, aiming to enhance the host’s immune activity against tumor cells by binding both tumor-enriched antigens (e.g., CEA, CEACAM, or CD276 antigen) and immune cells (mainly T cells using the CD3 receptor) (95).⁠ Cibisatamab (RO6958688, also known as CEA-TCB) is a T cell bispecific antibody targeting both CEA on tumor cells and CD3 on T cells, leading to crosslinking of tumor cells and lymphocyte T cell engagement and activation. Here, CD276 is linked to neoplasm.